# NS3763

| | |
|---|---|
| **Cat. No.:** | HY-107603 |
| **CAS No.:** | 70553-45-6 |
| **Molecular Formula:** | $C_{22}H_{16}N_2O_6$ |
| **Molecular Weight:** | 404.37 |
| **Target:** | iGluR |
| **Pathway:** | Membrane Transporter/Ion Channel; Neuronal Signaling |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |




## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | NS3763 is a selective and noncompetitive $GLU_{K5}$ receptor antagonist with an $IC_{50}$ of 1.6 μM. NS3763 does not show significant antagonistic properties on $GLU_{K6}$, AMPA or NMDA receptors[1]. |
| **$IC_{50}$ & Target** | IC50: 1.6 μM ($GLU_{K5}$ receptor)[1] |
| **In Vitro** | In human embryonic kidney HEK293 cells expressing homomeric $GLU_{K5}$ or $GLU_{K6}$ receptors, NS3763 displays selectivity for inhibition of domoate-induced increase in intracellular calcium mediated through the GLUK5 subtype ($IC_{50}$ = 1.6 μM) of kainate receptors compared with the GLUK6 subtype ($IC_{50}$ > 30 μM)[1].<br>NS3763 selectively inhibits l-glutamate- and domoate-evoked currents through $GLU_{K5}$ receptors in HEK293 cells[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Jeppe K Christensen, et al. In vitro characterization of 5-carboxyl-2,4-di-benzamidobenzoic acid (NS3763), a noncompetitive antagonist of GLUK5 receptors. J Pharmacol Exp Ther. 2004 Jun;309(3):1003-10.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA